Prevest Denpro Ltd (PREVEST) Fair Value & Analysis
Healthcare · IN · Market cap ₹4.7B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 6 days ago
Fair value updated Aug 13, 2026, revised from ₹328.28 to ₹348.86 (+6.3%) since Aug 12, 2026.
A solid business, but screening 12% overvalued on our models.
What matters now
- A fairly wide model range (₹213.36 to ₹420.90) leaves room in how you read the outcome.
- Our model range runs from ₹213.36 (bear) to ₹420.90 (bull), base ₹348.86. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 70/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
59‑month range ₹178.59 – ₹666.49 · fair‑value band ₹213.36 – ₹420.90 · the ₹395.55 price screens above the ₹348.86 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Prevest Denpro Ltd (PREVEST) currently trades at ₹395.55, while our model-based Fair Value estimate is ₹348.86, implying the stock looks roughly 11.8% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Prevest Denpro Ltd generated revenue of ₹718M at a net margin of 28.5%. Revenue grew 2.6% year over year. It earns a return on equity of 17.8%. The stock trades on a trailing P/E of 23.2. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹213.36 (bear case) to ₹420.90 (bull case); at ₹395.55, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 36% below its 52-week high and 24% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at -12%, PREVEST screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (₹411.35) versus Dividend Discount (₹15.12). Highest evidence: Growth DCF (80).
Notify me when PREVEST reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 32
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Prevest Denpro Limited engages in the manufacture and distribution of dental materials and equipment in India and internationally.
Full company description
Prevest Denpro Limited engages in the manufacture and distribution of dental materials and equipment in India and internationally. Its clinical products include adhesives, bonding agents, and etchants; composites; impression materials; retraction materials; auxiliaries; endodontics; temporary; cements and liners; finishing and polishing; orthodontics; and tooth whitening products. The company also provides laboratory products, such as acrylics, auxiliaries, base plates and waxes, and gypsum products. In addition, it offers oral care; 3D resins; and hygiene and disinfection products. Its products are used for endodontics, prosthodontics, periodontics, orthodontics, restorative dentistry, and aesthetic dentistry applications, as well as for the fabrication of prosthesis in dental laboratories. Prevest Denpro Limited was incorporated in 1999 and is based in Bari Brahmana, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Prevest Denpro Ltd reported revenue of ₹718M in FY2026 versus ₹381M in FY2022, a compound +17.2%/yr. Reported net income was ₹205M in FY2026, compounding +15.4%/yr from FY2022.
PREVEST screens 12% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 204 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $401.27 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €164.40 | €68.55 | -58% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $182.09 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | $226.00 | $187.89 | -17% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Coloplast A/S COLOB | kr 429.70 | kr 382.22 | -11% |
| Gan & Lee Pharmaceuticals., a biopharmaceutical company, 603087 | ¥77.48 | ¥27.22 | -65% |
Compare Prevest Denpro Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Prevest Denpro Ltd (PREVEST) overvalued or undervalued?
What is the fair value of PREVEST?
What is the quality score of PREVEST?
What is the revenue of Prevest Denpro Ltd (PREVEST)?
What is the net profit margin of PREVEST?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Prevest Denpro Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.